Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00253-021-11389-6 http://scihub22266oqcxt.onion/10.1007/s00253-021-11389-6 34142207!8211537!34142207     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Appl+Microbiol+Biotechnol 2021 ; 105 (12): 4931-4941 Nephropedia Template TP {{tp|p=34142207|t=2021. Plague vaccines: new developments in an ongoing search |pdf=|usr=}}{{34142207}} gab.com Text Plague vaccines: new developments in an ongoing search JO: Appl Microbiol Biotechnol http://www.kidney.de/pget.php?&tw=1&pmid=34142207 #FOAvip As the reality of pandemic threats challenges humanity, exemplified during the ongoing SARS-CoV-2 infections, the development of vaccines targeting these etiological agents of disease has become increasingly critical. Of paramount concern are novel and reemerging pathogens that could trigger such events, including the plague bacterium Yersinia pestis. Y. pestis is responsible for more human deaths than any other known pathogen and exists globally in endemic regions of the world, including the four corners region and Northern California in the USA. Recent cases have been scattered throughout the world, including China and the USA, with serious outbreaks in Madagascar during 2008, 2013-2014, and, most recently, 2017-2018. This review will focus on recent advances in plague vaccine development, a seemingly necessary endeavor, as there is no Food and Drug Administration-licensed vaccine available for human distribution in western nations, and that antibiotic-resistant strains are recovered clinically or intentionally developed. Progress and recent development involving subunit, live-attenuated, and nucleic acid-based plague vaccine candidates will be discussed in this review. KEY POINTS: * Plague vaccine development remains elusive yet critical. * DNA, animal, and live-attenuated vaccine candidates gain traction. Twit Text FOAVip Plague vaccines: new developments in an ongoing search ????Appl Microbiol Biotechnol http://www.kidney.de/pget.php?&tw=1&pmid=34142207 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34142207 #FOAvip English Wikipedia <ref>{{Cite pmid|34142207}}</ref> Plague vaccines: new developments in an ongoing search #MMPMID34142207 Rosenzweig JA; Hendrix EK; Chopra AK Appl Microbiol Biotechnol 2021[Jun]; 105 (12): 4931-4941 PMID34142207show ga As the reality of pandemic threats challenges humanity, exemplified during the ongoing SARS-CoV-2 infections, the development of vaccines targeting these etiological agents of disease has become increasingly critical. Of paramount concern are novel and reemerging pathogens that could trigger such events, including the plague bacterium Yersinia pestis. Y. pestis is responsible for more human deaths than any other known pathogen and exists globally in endemic regions of the world, including the four corners region and Northern California in the USA. Recent cases have been scattered throughout the world, including China and the USA, with serious outbreaks in Madagascar during 2008, 2013-2014, and, most recently, 2017-2018. This review will focus on recent advances in plague vaccine development, a seemingly necessary endeavor, as there is no Food and Drug Administration-licensed vaccine available for human distribution in western nations, and that antibiotic-resistant strains are recovered clinically or intentionally developed. Progress and recent development involving subunit, live-attenuated, and nucleic acid-based plague vaccine candidates will be discussed in this review. KEY POINTS: * Plague vaccine development remains elusive yet critical. * DNA, animal, and live-attenuated vaccine candidates gain traction. |*COVID-19[MESH] |*Plague[MESH] |*Plague Vaccine[MESH] |*Yersinia pestis[MESH] |Animals[MESH] |Antibodies, Bacterial[MESH] |China[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Plague vaccines: new developments in an ongoing search (epmc).pdf DeepDyve Pubget Overpricing